ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

Firmonertinib shows strong Phase 1b efficacy in EGFR PACC-mutant NSCLC, but pivotal data is pending.

What the company is saying

ArriVent BioPharma, Inc. is highlighting the publication of Phase 1b trial results for firmonertinib in EGFR PACC-mutant NSCLC, positioning the drug as a potential first oral, chemotherapy-free targeted therapy for this underserved population. The company emphasizes robust efficacy data, including a 43% overall response rate (ORR) at 160 mg and 68% ORR at 240 mg, with median progression-free survival (PFS) of 11.1 and 16.0 months, respectively. They stress the lack of a targeted standard of care for the 12% of EGFR-mutant NSCLC patients with PACC mutations, framing firmonertinib as purpose-built for this need. The announcement features remarks from Xiuning Le, MD, Ph.D., and CEO Bing Yao, Ph.D., both expressing confidence in the drug’s potential and its unique molecular fit for PACC mutations. The company is advancing to a global Phase 3 ALPACCA trial, comparing firmonertinib to investigator’s choice of osimertinib or afatinib. Regulatory achievements are noted, with firmonertinib already approved in China for several EGFR mutation subtypes and holding U.S. FDA Breakthrough Therapy and Orphan Drug designations for related indications. Safety is described as manageable and consistent with prior studies, but no quantitative safety data is provided.

What the data suggests

The disclosed figures show firmonertinib achieved a 43% confirmed ORR at 160 mg and a 68% ORR at 240 mg in front-line EGFR PACC-mutant NSCLC, with median PFS of 11.1 and 16.0 months, respectively, as assessed by blinded independent central review. Among 17 patients with baseline brain metastases, the drug produced a 47% intracranial ORR, including 41% complete responses. Molecular response data indicate that 80% of evaluable patients achieved ctDNA clearance by cycle 3, correlating with higher ORR (70% vs. 20%) and longer PFS (15.1 vs. 3.0 months) compared to those without clearance. NSCLC represents 85% of global lung cancer cases, with PACC mutations accounting for 12% of EGFR mutations and exon 20 insertions for 9%. The trial data are robust for a Phase 1b study, but no late-stage (Phase 3) efficacy or safety outcomes are yet available. The safety profile is described as manageable, but no adverse event rates or specifics are disclosed. Firmonertinib is approved in China for several EGFR mutation-driven NSCLC subtypes, but not yet for PACC mutations outside clinical trials. The evidence supports strong early efficacy, but pivotal regulatory and commercial milestones remain ahead.

Analysis

The announcement presents positive Phase 1b clinical data for firmonertinib in a specific NSCLC population, with detailed efficacy metrics (ORR, PFS, molecular response) and references to regulatory designations and ongoing trials. However, the tone is somewhat inflated by forward-looking statements about paradigm change and global impact, despite the fact that pivotal Phase 3 data and regulatory approvals outside China are still pending. The majority of the measurable progress is limited to early-phase clinical results, with no financial, commercial, or late-stage regulatory milestones disclosed. Safety is described as 'manageable' without quantitative detail. The forward-looking ratio is moderate, as several key claims (potential to change treatment paradigm, ongoing Phase 3, future pipeline) are aspirational. The execution distance is long-term, as the next catalyst (Phase 3 data) is not imminent. No large capital outlay is disclosed in this release.

Risk flags

• ●The primary risk is clinical and regulatory: firmonertinib’s efficacy and safety in a larger, more diverse population remain unproven until Phase 3 results are available, and regulatory approval for the PACC-mutant indication outside China is not assured.
• ●Commercial risk is significant, as the drug is not yet approved for EGFR PACC-mutant NSCLC outside clinical trials, and the company faces competition from established therapies such as osimertinib and afatinib, which are being used as comparators in the ongoing Phase 3 trial.
• ●Disclosure risk is present, as the announcement provides no quantitative safety data or adverse event rates, limiting the ability to assess risk-benefit and compare tolerability to existing treatments.
• ●Execution risk exists around patient enrollment, trial completion, and subsequent regulatory submissions, with no stated milestones or timelines, increasing uncertainty on when or if commercial value will be realized.

Bottom line

ArriVent BioPharma’s Phase 1b results for firmonertinib in EGFR PACC-mutant NSCLC demonstrate high response rates and encouraging progression-free survival, addressing a clear unmet need for the 12% of EGFR-mutant patients with these mutations. The data are robust for an early-phase trial, but the lack of quantitative safety detail and the absence of Phase 3 or regulatory outcomes mean the investment case remains speculative. The company’s confidence is supported by regulatory designations and approval in China for other EGFR mutations, but the pivotal ALPACCA Phase 3 trial is still enrolling and no timeline for data or approval is given. Investors should recognize that while the clinical signal is strong, commercial and regulatory risks are high and value realization is not imminent. The most important takeaway is that firmonertinib is a promising candidate for a large, underserved NSCLC subpopulation, but the investment thesis hinges on successful Phase 3 results and subsequent approvals.

Announcement summary

(NASDAQ:AVBP) ArriVent BioPharma, Inc. announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell, highlighting preclinical and clinical findings for treatment-naïve patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). EGFR PACC-mutant NSCLC accounts for approximately 12% of EGFR-mutant tumors and currently lacks an established targeted standard of care. Firmonertinib demonstrated enhanced in vitro potency versus osimertinib due to its unique trifluoroethoxy side chain, which creates additional contact points for binding to PACC-mutated EGFR's kinase domain. In the clinical trial, firmonertinib achieved a 43% confirmed overall response rate (ORR) at 160 mg and a 68% confirmed ORR at 240 mg, with median progression-free survival (PFS) of 11.1 months and 16.0 months, respectively, as determined by blinded independent central review (BICR) in front-line EGFR PACC-mutant NSCLC. Among patients with baseline brain metastases, firmonertinib showed a 47% (8/17) confirmed intracranial ORR, including 41% complete responses. Circulating tumor DNA (ctDNA) clearance correlated with outcomes, as 80% of evaluable patients achieved complete molecular response by cycle 3, with higher ORR (70% vs. 20%) and longer median PFS (15.1 vs. 3.0 months) than those without clearance. The safety profile of firmonertinib was manageable and consistent with prior clinical studies. ArriVent is evaluating firmonertinib versus investigator's choice of osimertinib or afatinib as first-line treatment for patients with locally advanced or metastatic EGFR PACC-mutant NSCLC in the FURMO-006 (NCT07185997) trial. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective EGFR inhibitor, active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is approved in China for first-line advanced NSCLC patients with EGFR exon 19 deletion or L858R mutations, previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, and for exon 20 insertion mutations after platinum-containing chemotherapy. Firmonertinib has received U.S. FDA Breakthrough Therapy Designation for previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations, and U.S. FDA Orphan Drug Designation for NSCLC with EGFR, HER2, or HER4 mutations. NSCLC accounts for approximately 85% of all lung cancer cases globally, and EGFR exon 20 insertion mutations constitute approximately 9% of all EGFR mutations, while PACC mutations represent approximately 12% of all EGFR mutations. PACC mutations are a distinct set of approximately 70 mostly missense activating mutations within the kinase domain of EGFR. Patients with PACC mutations have limited treatment options and no broadly utilized standard of care for first-line treatment.

Disagree with this article?